[
  {
    "Drugs": [{ "name": "abacavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "abacavir" },
      { "name": "dolutegravir" },
      { "name": "lamivudine" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "abacavir" },
      { "name": "lamivudine" },
      { "name": "zidovudine" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "abacavir" }, { "name": "lamivudine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "abatacept" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "abciximab" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "abemaciclib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "abiraterone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antiandrogens",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acalabrutinib" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acamprosate" }],
    "Category": "B2",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acarbose" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acetazolamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Carbonic anhydrase inhibitor",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acetazolamide (ophthalmic)" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acetylcholine" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acetylcysteine" }],
    "Category": "B2",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acetylcysteine (inhaled)" }],
    "Category": "B2",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Expectorants and mucolytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acetylcysteine (intravenous)" }],
    "Category": "B2",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aciclovir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aciclovir (topical)" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiviral",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "acitretin" }],
    "Category": "X",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Systemic",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aclidinium bromide" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "aclidinium bromide" },
      { "name": "eformoterol fumarate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "actinomycin D (dactinomycin)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "Observation": "Possibilité de malformations congénitales (observées uniquement chez l’animal)"
  },
  {
    "Drugs": [{ "name": "adalimumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "adapalene" }],
    "Category": "D",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": " ",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "adefovir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "adenosine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "adrenaline (epinephrine)" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "afamelanotide" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs Used in Dermatology",
    "ClassificationLevel2": "Systemic",
    "ClassificationLevel3": " ",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "afatinib" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aflibercept" }],
    "Category": "D",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "agalsidase alfa" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "agalsidase beta" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "agomelatine" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alatrofloxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "albendazole" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Anthelmintics",
    "ClassificationLevel3": " ",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "albutrepenonacog alfa" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alcuronium" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aldesleukin" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alectinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alefacept" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alemtuzumab" }],
    "Category": "B2",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alendronate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "Bisphosphonates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alfentanil" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "alfuzosin" }],
    "Category": "B2",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Prostate hyperplasia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alginates" }, { "name": "antacids" }],
    "Category": "A",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alglucerase" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alglucosidase alfa" }],
    "Category": "B1",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alimemazine" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": " ",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alirocumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aliskiren" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin II receptor antagonists and renin inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "allergen pollen extract of 5 grasses" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "allopurinol" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Agents used in gout and hyperuricaemia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alogliptin" }, { "name": "metformin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alogliptin benzoate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alpelisib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alpha-1-proteinase inhibitor" }],
    "Category": "B2",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "alprazolam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "alprenolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "alteplase" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "altretamine (hexamethylmelamine)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amantadine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ambenonium chloride" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Myasthenia Gravis",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ambrisentan" }],
    "Category": "X",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Endothelin receptor antagonist",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amethocaine (tetracaine)" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amifampridine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": " ",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amifostine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Non-cytotoxic supportive therapy",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amikacin" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Aminoglycosides",
    "Observation": "Lésions de l’oreille fœtale (ototoxicité) entraînant une surdité"
  },
  {
    "Drugs": [{ "name": "amiloride" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Potassium sparing diuretics",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aminocaproic acid" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aminoglutethimide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aminoglutethimide" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hormonal agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aminolevulinic acid HCl" }],
    "Category": "C",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amiodarone" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amisulpride" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amitriptyline" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amlodipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "amlodipine" }, { "name": "atorvastatin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "amlodipine" },
      { "name": "hydrochlorothiazide" },
      { "name": "valsartan" }
    ],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amlodipine" }, { "name": "olmesartan medoxomil" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "amlodipine" },
      { "name": "olmesartan medoxomil" },
      { "name": "hydrochlorothiazide" }
    ],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amlodipine" }, { "name": "telmisartan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amlodipine" }, { "name": "valsartan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ammonium chloride" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Expectorants and mucolytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amobarbital" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "Barbiturates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amorolfine" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amoxicillin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amphotericin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amphotericin B (liposomal)" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": "Pas de risque accru de malformations congénitales, mais aucune étude bien conçue n’a été menée chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "ampicillin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amprenavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amsacrine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "amylobarbitone (amobarbital)" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "Barbiturates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "anagrelide" }],
    "Category": "B3",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "anakinra" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "anastrozole" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ancestim" }],
    "Category": "B2",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "anecortave" }],
    "Category": "B1",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "anidulafungin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "anistreplase" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System Fibrinolytic agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "anti-thymocyte immunoglobulin" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "antithrombin III" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "apalutamide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "apixaban" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "apomorphine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "apraclonidine" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": " ",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "apremilast" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aprepitant" }],
    "Category": "B1",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Non-cytotoxic supportive therapy",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aprotinin" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "argipressin" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antidiuretics",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aripiprazole" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "armodafinil" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "CNS stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "arsenic trioxide" }],
    "Category": "X",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "artemether with lumefantine" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "articaine" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "articaine" }, { "name": "adrenaline" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "asenapine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "asfotase alfa (rch)" }],
    "Category": "C",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "asparaginase" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aspirin" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "aspirin" }, { "name": "dipyridamole" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "asunaprevir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atazanavir" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atazanavir" }, { "name": "cobicistat" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atenolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "atezolizumab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atomoxetine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "CNS stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atorvastatin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atorvastatin" }, { "name": "ezetimibe" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atovaquone" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atracurium" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atropine" }],
    "Category": "A",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antispasmodics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atropine" }],
    "Category": "A",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "atropine methonitrate" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "auranofin" }],
    "Category": "B3",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Antirheumatoid agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aurothioglucose" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Antirheumatoid agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "avalglucosidase alfa" }],
    "Category": "B1",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "avelumab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "axicabtagene ciloleucel" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "axitinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "azacitidine" }],
    "Category": "X",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "azatadine" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "azathioprine" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "azelaic acid" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "azelastine" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "azelastine hydrochloride" },
      { "name": "fluticasone propionate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "azithromycin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Macrolide antibiotics",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "azlocillin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "aztreonam" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "baclofen" }],
    "Category": "B3",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "baloxavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "balsalazide" }],
    "Category": "C",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "baricitinib" }],
    "Category": "D",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Antirheumatoid agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "basiliximab" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "BCG (Mycobacterium bovis)" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "becaplermin" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "beclometasone" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Inhalation/intranasal",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "beclomethasone" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Preventative aerosols and inhalations",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "belatacept" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "belimumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "belladonna" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bendamustine hydrochloride" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bendrofluazide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "benralizumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benserazide" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benserazide" }, { "name": "levodopa" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benzathine penicillin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benzatropine" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benzhexol (trihexyphenidyl)" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benzoyl peroxide" }, { "name": "adapalene" }],
    "Category": "D",
    "ClassificationLevel1": "",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benzoyl peroxide" }, { "name": "clindamycin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benzydamine (topical oropharyngeal)" }],
    "Category": "B2",
    "ClassificationLevel1": "Mouth Preparations",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benzyl benzoate" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiparasitics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "benzylpenicillin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "betahistine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "betamethasone acetate" }, { "name": "betamethasone" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "betamethasone dipropionate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [
      { "name": "betamethasone dipropionate" },
      { "name": "calcipotriol" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Drugs Used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "betamethasone valerate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "betaxolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "betaxolol (ophthalmic)" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bethanechol" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bethanechol" }],
    "Category": "B2",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Bladder function disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bevacizumab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bevantolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "bezlotoxumab" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bicalutamide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "bictegravir" },
      { "name": "emtricitabine" },
      { "name": "tenofovir alafenamide" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bifonazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bimatoprost" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bimatoprost" }, { "name": "timolol" }],
    "Category": "C",
    "ClassificationLevel1": "",
    "ClassificationLevel2": "Ophthalmic Drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "binimetinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bioallethrin" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiparasitics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "biperiden" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bisacodyl" }],
    "Category": "A",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Laxatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bismuth subcitrate" }],
    "Category": "B2",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bisoprolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "bivalirudin" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "bleomycin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "blinatumomab (rch)" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "boceprevir" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "boceprevir with ribavirin and peginterferon alfa" }],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bortezomib" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bosentan" }],
    "Category": "X",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Endothelin receptor antagonist",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "botulinum toxin type A" }],
    "Category": "B3",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brentuximab vedotin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bretylium tosilate" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brexpiprazole" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brexucabtagene autoleucel" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brigatinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brimonidine" }, { "name": "brinzolamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brimonidine" }, { "name": "timolol" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brimonidine tartrate" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brinzolamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brinzolamide" }, { "name": "timolol" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brivaracetam" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brolucizumab" }],
    "Category": "D",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bromazepam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "bromhexine" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Expectorants and mucolytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bromocriptine (injection)" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bromocriptine (oral)" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "brompheniramine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "budesonide" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Inhalation/intranasal",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "budesonide" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Preventative aerosols and inhalations",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "budesonide (systemic)" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bumetanide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "bupivacaine" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "bupivacaine" }, { "name": "fentanyl" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal and anti-inflammatory agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "buprenorphine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Aucune preuve de risque accru de malformations congénitales, mais pourrait avoir d’autres effets néfastes sur le fœtus ou le nouveau-né. Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né en raison de l’interruption du passage du médicament dans le placenta"
  },
  {
    "Drugs": [{ "name": "bupropion" }],
    "Category": "B2",
    "ClassificationLevel1": "Agents used in dependency states",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Effets néfastes observés chez les animaux, mais preuves contradictoires concernant le risque de malformations congénitales chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "burosumab" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "buspirone" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antianxiety agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "busulfan" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": "Anomalies congénitales comme un développement insuffisant de la mandibule, une fente palatine, une anomalie de développement des os du crâne, des anomalies de la colonne vertébrale, de l’oreille et un pied bot. Croissance insuffisante du fœtus (retard de croissance)"
  },
  {
    "Drugs": [{ "name": "butoconazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cabazitaxel" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cabergoline" }],
    "Category": "B1",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cabotegravir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cabozantinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "caffeine" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "CNS stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "calcipotriol" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "calcitonin" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "calcitonin salmon" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "calcitriol" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "calcium carbimide" }],
    "Category": "A",
    "ClassificationLevel1": "Agents used in dependency states",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "canagliflozin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "canakinumab" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "candesartan cilexetil" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin II receptor antagonists and renin inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "cannabidiol" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "capecitabine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "caplacizumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "captopril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "carbachol" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carbamazepine" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Risque accru d’anomalies congénitales, notamment des malformations du tube neural (comme le spina bifida). Problèmes hémorragiques chez le nouveau-né (maladie hémorragique du nouveau-né), qui peuvent être prévenus par la prise quotidienne de vitamine K orale, un mois avant l’accouchement ou si on injecte de la vitamine K au nouveau-né, peu après la naissance"
  },
  {
    "Drugs": [{ "name": "carbetocin" }],
    "Category": "C",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Agents acting on the uterus",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carbidopa" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "carbidopa" },
      { "name": "entacapone" },
      { "name": "levodopa" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carbidopa" }, { "name": "levodopa" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carbimazole" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antithyroid agents",
    "ClassificationLevel3": "",
    "Observation": "Glande thyroïde augmentée de volume et déficitaire chez le fœtus. Anomalies du cuir chevelu chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "carboplatin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carboprost" }],
    "Category": "D",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Agents acting on the uterus",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carfilzomib" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carglumic acid" }],
    "Category": "B1",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cariprazine" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carmustine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "carvedilol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "cascara" }],
    "Category": "A",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Laxatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "casirivimab" }, { "name": "imdevimab" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "caspofungin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefaclor" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefalexin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefalotin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefamandole" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefazolin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefepime" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefodizime" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefotaxime" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefotetan" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefoxitin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefpirome" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefpodoxime" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ceftaroline fosamil" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ceftazidime" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ceftolozane" }, { "name": "tazobactam" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ceftriaxone" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cefuroxime" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "celecoxib" }],
    "Category": "B3",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "cemiplimab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ceritinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cerivastatin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cerliponase alfa" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "certolizumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and immune system",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cetirizine" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cetrorelix" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cetuximab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cetylpyridinium" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chenodeoxycholic acid" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Cholelitholytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chloral hydrate" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlorambucil" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": "Anomalies congénitales comme un développement insuffisant de la mandibule, une fente palatine, une anomalie de développement des os du crâne, des anomalies de la colonne vertébrale, de l’oreille et un pied bot. Croissance insuffisante du fœtus (retard de croissance)"
  },
  {
    "Drugs": [{ "name": "chloramphenicol" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": "Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD) Potentiellement, syndrome du bébé gris (une pathologie grave et souvent fatale)"
  },
  {
    "Drugs": [{ "name": "chloramphenicol (ophthalmic)" }],
    "Category": "A",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD) Potentiellement, syndrome du bébé gris (une pathologie grave et souvent fatale)"
  },
  {
    "Drugs": [{ "name": "chlorcyclizine" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlordiazepoxide" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "chlorhexidine" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlormethiazole" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlormethine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chloroquine (prophylaxis)" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chloroquine (treatment)" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlorothiazide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "chlorphenamine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlorpromazine" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlorpropamide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlorquinaldol" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "chlortalidone" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "cholera vaccine (killed)" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cholic acid" }],
    "Category": "B2",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Cholelitholytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "choriogonadotropin alfa (rch)" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Ovulation inducers",
    "ClassificationLevel3": "Gonadotrophins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ciclesonide" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Inhalation/intranasal",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "ciclesonide" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Preventative aerosols and inhalations",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ciclopirox" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ciclosporin" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cidofovir" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cilazapril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "cilostazol" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cimetidine" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cinacalcet" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cinchocaine" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ciprofloxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "cisapride" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cisatracurium besilate" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cisplatin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "citalopram" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Selective serotonin reuptake inhibitors (SSRIs)",
    "Observation": "Lorsque le citalopram est administré au cours du premier trimestre, risque accru de malformations congénitales (notamment cardiaques). Lorsque le citalopram est administré au cours du troisième trimestre, syndrome de sevrage (qui comprend vertiges, anxiété, irritabilité, fatigue, nausées, frissons, et douleurs musculaires) et hypertension artérielle pulmonaire persistante du nouveau-né (les artères pulmonaires restent rétrécies après l’accouchement, ce qui limite le flux sanguin vers les poumons et donc la quantité d’oxygène dans le sang)"
  },
  {
    "Drugs": [{ "name": "cladribine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clarithromycin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Macrolide antibiotics",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clavulanic acid" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clemastine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clevidipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "clindamycin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clindamycin" }],
    "Category": "A",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Topical vaginal medication",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clindamycin" }, { "name": "tretinoin" }],
    "Category": "D",
    "ClassificationLevel1": "Drugs Used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clioquinol" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clobazam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "clodronate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "Bisphosphonates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clofarabine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clofazimine" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antituberculotics and antileprotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clofibrate" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clomifene" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Ovulation inducers",
    "ClassificationLevel3": "Gonadotrophins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clomipramine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clonazepam" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clonazepam" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "clonidine" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clopamide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "clopidogrel" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "clopidogrel" }, { "name": "aspirin" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus. Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "clorazepate" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "clotrimazole" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clotrimazole" }],
    "Category": "A",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Topical vaginal medication",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cloxacillin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "clozapine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cobicistat" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cobimetinib fumarate" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "codeine" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal - anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "codeine" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Antitussives",
    "ClassificationLevel3": "",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "colaspase (asparaginase)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "colchicine" }],
    "Category": "D",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Agents used in gout and hyperuricaemia",
    "ClassificationLevel3": "",
    "Observation": "Possibilité de malformations congénitales (observées chez l’animal). Anomalies des spermatozoïdes chez les garçons"
  },
  {
    "Drugs": [{ "name": "colestipol" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "colestyramine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "colistimethate" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "colistin IV with colistimethate" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "collagenase clostridium histolyticum" }],
    "Category": "B1",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "conjugated estrogens" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "corifollitropin alfa" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Ovulation inducers",
    "ClassificationLevel3": "Gonadotrophins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "corticotrophin" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cortisone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Systemic",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "COVID-19 Vaccine - ChAdOx1-S" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Les données concernant la sécurité d’emploi des vaccins contre le COVID-19 chez la femme enceinte sont limitées. Il est recommandé aux femmes enceintes et allaitantes de discuter des risques et des bénéfices de la vaccination avec leur professionnel de santé"
  },
  {
    "Drugs": [{ "name": "COVID-19 Vaccine - elasomeran" }],
    "Category": "B1",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Les données concernant la sécurité d’emploi des vaccins contre le COVID-19 chez la femme enceinte sont limitées. Il est recommandé aux femmes enceintes et allaitantes de discuter des risques et des bénéfices de la vaccination avec leur professionnel de santé"
  },
  {
    "Drugs": [{ "name": "COVID-19 Vaccine - SARS-CoV-2 rS (NVX-CoV2373)" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": "Les données concernant la sécurité d’emploi des vaccins contre le COVID-19 chez la femme enceinte sont limitées. Il est recommandé aux femmes enceintes et allaitantes de discuter des risques et des bénéfices de la vaccination avec leur professionnel de santé"
  },
  {
    "Drugs": [{ "name": "COVID-19 Vaccine - tozinameran" }],
    "Category": "B1",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Les données concernant la sécurité d’emploi des vaccins contre le COVID-19 chez la femme enceinte sont limitées. Il est recommandé aux femmes enceintes et allaitantes de discuter des risques et des bénéfices de la vaccination avec leur professionnel de santé"
  },
  {
    "Drugs": [{ "name": "COVID-19 Vaccine Ad26.COV2.S" }],
    "Category": "B1",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Les données concernant la sécurité d’emploi des vaccins contre le COVID-19 chez la femme enceinte sont limitées. Il est recommandé aux femmes enceintes et allaitantes de discuter des risques et des bénéfices de la vaccination avec leur professionnel de santé"
  },
  {
    "Drugs": [{ "name": "crisaborole" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs Used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "crizotinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "crotamiton" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiparasitics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cyclizine" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cyclopenthiazide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "cyclopentolate" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cyclophosphamide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": "Anomalies congénitales comme un développement insuffisant de la mandibule, une fente palatine, une anomalie de développement des os du crâne, des anomalies de la colonne vertébrale, de l’oreille et un pied bot. Croissance insuffisante du fœtus (retard de croissance)"
  },
  {
    "Drugs": [{ "name": "cyproheptadine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cyproterone acetate (10 mg daily or higher PO)" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antiandrogens",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cyproterone acetate (2 mg daily PO)" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antiandrogens",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cysteamine bitartrate (mercaptamine bitartrate)" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "cytarabine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dabigatran etexilate" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "dabrafenib mesilate" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dacarbazine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "daclatasvir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "daclizumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dactinomycin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": "Possibilité de malformations congénitales (observées uniquement chez l’animal)"
  },
  {
    "Drugs": [{ "name": "dalfopristin with quinupristin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dalteparin" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "danaparoid" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "danazol" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "dantrolene" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dapagliflozin" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dapagliflozin" }, { "name": "saxagliptin" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dapagliflozin" }, { "name": "metformin" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dapoxetine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Selective serotonin reuptake inhibitors (SSRIs)",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dapsone" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antituberculotics and antileprotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "daptomycin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "daratumumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "darbepoetin alfa" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "darifenacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Prostate hyperplasia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "darolutamide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "darunavir" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dasatinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "daunorubicin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "deferasirox" }],
    "Category": "C",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "deferiprone" }],
    "Category": "D",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "defibrotide" }],
    "Category": "D",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "degarelix" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "delavirdine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "demeclocycline" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Tetracyclines",
    "Observation": "Ralentissement de la croissance osseuse, jaunissement permanent des dents et augmentation du risque de caries chez l’enfant. Parfois, insuffisance hépatique chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "denosumab" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "desferrioxamine" }],
    "Category": "B3",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "desflurane" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "desipramine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "desirudin" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "desloratadine" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "desmopressin" }],
    "Category": "B1",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antidiuretics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "desogestrel with ethinylestradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Oral contraceptives",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "desonide" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "desvenlafaxine" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dexamethasone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Systemic",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "dexamfetamine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "CNS stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dexchlorphenamine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dexfenfluramine" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Anorectic and weight reducing agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dexmedetomidine" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dextromethorphan" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Antitussives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dextromoramide" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "dextropropoxyphene" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "diazepam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "diazoxide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diclofenac" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "dicloxacillin" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dicyclomine hydrochloride" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Laxatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "didanosine" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dienoestrol" }],
    "Category": "X",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dienogest with ethinylestradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Oral contraceptives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dienosliterol" }],
    "Category": "B1",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Topical vaginal medication",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diethylcarbamazine" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Anthelmintics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diethylpropion" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Anorectic and weight reducing agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diflunisal" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "digoxin and other cardiac glycosides" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Cardiac inotropic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "digoxin immune fab" }],
    "Category": "B2",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "digoxin-specific antibody fragment F(Ab) (Ovine)" }],
    "Category": "B2",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dihydrocodeine" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "dihydrocodeine" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Antitussives",
    "ClassificationLevel3": "",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "dihydroergotamine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dihydrotachysterol" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diltiazem" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "dimenhydrinate" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dimethyl fumarate" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dinoprost" }],
    "Category": "C",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Agents acting on the uterus",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dinoprostone (prostaglandin E2)" }],
    "Category": "C",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Agents acting on the uterus",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dinutuximab beta" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diphenhydramine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diphenhydramine" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diphenoxylate" }],
    "Category": "C",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diphenylamine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diphenylpyraline" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diphtheria-tetanus vaccine" }],
    "Category": "A",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "diphtheria-tetanus-pertussis vaccine" }],
    "Category": "A",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      {
        "name": "diphtheria-tetanus-pertussis-hepatitis B- inactivated poliomyelitis-Haemophilus \\ influenzae type b conjugate vaccine"
      }
    ],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": "Risques potentiels, mais inconnus"
  },
  {
    "Drugs": [
      {
        "name": "diphtheria-tetanus-pertussis-hepatitis B- inactivated poliomyelitis-Haemophilus\\influenzae type b vaccine"
      }
    ],
    "Category": "B1 or B2 (depending on brand of vaccine)",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": "Risques potentiels, mais inconnus"
  },
  {
    "Drugs": [
      {
        "name": "diphtheria-tetanus-pertussis-inactivated poliomyelitis vaccine"
      }
    ],
    "Category": "A",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": "Risques potentiels, mais inconnus"
  },
  {
    "Drugs": [{ "name": "dipivefrine" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dipyridamole" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "disopyramide" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "disulfiram" }],
    "Category": "B2",
    "ClassificationLevel1": "Agents used in dependency states",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dithranol" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dobutamine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "docetaxel" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "docusate sodium" }],
    "Category": "A",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Laxatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dofetilide" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dolasetron" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dolutegravir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "dolutegravir" },
      { "name": "abacavir" },
      { "name": "lamivudine" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "domperidone" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "donepezil" }],
    "Category": "B3",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dopamine" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "doripenem" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dornase alfa" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dorzolamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dorzolamide" }, { "name": "timolol" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dosulepin" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dothiepin (dosulepin)" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "doxazosin" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "doxepin" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "doxorubicin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": "Problèmes cardiaques, en fonction de la dose prise. Anomalies congénitales"
  },
  {
    "Drugs": [{ "name": "doxycycline" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Tetracyclines",
    "Observation": "Ralentissement de la croissance osseuse, jaunissement permanent des dents et augmentation du risque de caries chez l’enfant. Parfois, insuffisance hépatique chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "doxycycline (antimalarial)" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "doxylamine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dronedarone" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "droperidol" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Butyrophenones",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "drospirenone with ethinylestradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Oral contraceptives",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "drotrecogin alfa" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dulaglutide" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "duloxetine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Selective serotonin reuptake inhibitors (SSRIs)",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dupilumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "durvalumab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dutasteride" }],
    "Category": "X",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Prostate hyperplasia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "dydrogesterone with estradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Progestogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "econazole" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "econazole" }],
    "Category": "A",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Topical vaginal medication",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ecothiopate" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eculizumab" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "efalizumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "efavirenz" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eflornithine" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eformoterol (formoterol)" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "efraloctocog alfa (rhu)" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eftrenonacog alfa (rhu)" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "elbasvir" }, { "name": "grazoprevir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eletriptan" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eliglustat" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "elosulfase alfa (rch)" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "elotuzumab" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eltrombopag" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "elvitegravir" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      {
        "name": "elvitegravir"
      },
      { "name": "cobicistat" },
      { "name": "emtricitabine" },
      { "name": "tenofovir alafenamide" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "emetine" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Expectorants and mucolytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "emicizumab" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "empagliflozin" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "empagliflozin" }, { "name": "linagliptin" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "empagliflozin" }, { "name": "metformin" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "emtricitabine" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "emtricitabine" },
      { "name": "ripilvirine" },
      { "name": "tenofovir alafenamide" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "emtricitabine" }, { "name": "tenofovir alafenamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "emtricitabine" },
      { "name": "tenofovir disoproxil fumarate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "emtricitabine" },
      { "name": "tenofovir disoproxil fumarate" },
      { "name": "rilpivirine" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "emtricitabine" },
      { "name": "tenofovir disoproxil maleate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "enalapril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "enasidenib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "encorafenib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "enflurane" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "enfuvirtide" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "enoxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "enoxaparin" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "entacapone" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "entecavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "entrectinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "enzalutamide" }],
    "Category": "X",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ephedrine" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ephedrine" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "epirubicin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eplerenone" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "",
    "Observation": "Avec l’éplérénone, pas de risque accru de malformations congénitales chez l’animal, mais aucune étude bien conçue n’a été menée chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "epoetin alfa" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "epoetin beta (rch)" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "epoetin lambda (rch)" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "epoprostenol" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eprosartan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin II receptor antagonists and renin inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "eptacog alfa (activated Factor VII - rch)" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eptifibatide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "eptinezumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eptotermin alfa" }],
    "Category": "D",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Osteogenic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "erenumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ergometrine" }],
    "Category": "C",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Agents acting on the uterus",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ergotamine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eribulin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "erlotinib" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ertapenem" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ertugliflozin pyroglutamic acid" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "ertugliflozin pyroglutamic acid; Metformin hydrochloride" }
    ],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      {
        "name": "ertugliflozin pyroglutamic acid; sitagliptin phosphate monohydrate"
      }
    ],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "erythromycin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Macrolide antibiotics",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "erythropoietin" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "escitalopram" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Selective serotonin reuptake inhibitors (SSRIs)",
    "Observation": "Lorsque l’escitalopram est administré au cours du troisième trimestre, syndrome de sevrage et hypertension artérielle pulmonaire persistante du nouveau-né"
  },
  {
    "Drugs": [{ "name": "esketamine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "eslicarbazepine acetate" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "esmolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "esomeprazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "estradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "estramustine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "estriol" }],
    "Category": "B1",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "estropipate" }],
    "Category": "B1",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "etacrynic acid" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "etanercept" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ethambutol" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antituberculotics and antileprotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ethinylestradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ethosuximide" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "etidocaine" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "etidronate disodium" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "etonogestrel" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "etoposide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "etoricoxib" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "etravirine" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "etretinate" }],
    "Category": "X",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Systemic",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "everolimus" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "evolocumab (rch)" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "exemestane" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "exenatide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ezetimibe" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "factor IX (human)" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "factor IX (r CHO)" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "famciclovir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "famotidine" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fampridine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "febuxostat" }],
    "Category": "B1",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Agents used in gout and hyperuricaemia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "felodipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "fenfluramine" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Anorectic and weight reducing agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fenofibrate" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fenoterol" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fenoterol" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fentanyl" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal-anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "fentanyl" }, { "name": "ropivacaine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal and anti-inflammatory agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ferric carboxymaltose" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ferucarbotran" }],
    "Category": "B1",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fexofenadine" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fibrin" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fibrinogen" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fibrinogen" }, { "name": "thrombin" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fibronectin" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fidaxomicin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "filgrastim" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "finasteride" }],
    "Category": "X",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "finasteride" }],
    "Category": "X",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Prostate hyperplasia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "finerenone" }],
    "Category": "D",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fingolimod" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "flecainide" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fleroxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "flucloxacillin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluconazole" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": "Pas de risque accru de malformations congénitales après une dose unique faible. Lorsque de fortes doses sont administrées pendant une grande partie ou l’intégralité du premier trimestre, risque accru de malformations congénitales, telles que des anomalies cardiaques, faciales, des côtes ou des membres"
  },
  {
    "Drugs": [{ "name": "flucytosine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fludarabine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fludrocortisone (systemic)" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Systemic",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "fludrocortisone (topical)" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Topical",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "flumazenil" }],
    "Category": "B3",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "flumetasone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Topical",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "flunisolide" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Inhalation/intranasal",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "flunitrazepam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "fluocinolone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Topical",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "fluocortolone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Topical",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "fluorescein sodium (systemic)" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluorometholone" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluorouracil" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluoxetine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Selective serotonin reuptake inhibitors (SSRIs)",
    "Observation": "Lorsque la fluoxétine est administrée au cours du troisième trimestre, syndrome de sevrage et hypertension artérielle pulmonaire persistante du nouveau-né"
  },
  {
    "Drugs": [{ "name": "fluoxymesterone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Androgens and anabolic steroids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "flupenthixol" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluphenazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "flurazepam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "flurbiprofen" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluticasone furoate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Inhalation/intranasal",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [
      { "name": "fluticasone furoate" },
      { "name": "vilanterol trifenatate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System Inhalational agents",
    "ClassificationLevel2": "Preventative aerosols and inhalations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluticasone propionate" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Preventative aerosols and inhalations",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "fluticasone propionate" },
      { "name": "eformoterol fumarate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "fluticasone propionate" },
      { "name": "salmeterol xinafoate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluvastatin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fluvoxamine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Selective serotonin reuptake inhibitors (SSRIs)",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "folic acid" }],
    "Category": "A",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "folinic acid (leucovorin)" }],
    "Category": "A",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "follicle stimulating hormone (recombinant human)" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System Ovulation inducers",
    "ClassificationLevel2": "Gonadotrophins",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "follitropin alfa" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "follitropin beta" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "follitropin delta" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fomepizole" }],
    "Category": "B2",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fomivirsen" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fondaparinux" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "formoterol" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fosamprenavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fosaprepitant" }],
    "Category": "B2",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Non-cytotoxic supportive therapy",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "foscarnet" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fosfomycin trometamol" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fosinopril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "fostemsavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "fotemustine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "framycetin" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Aminoglycosides",
    "Observation": "Lésions de l’oreille fœtale (ototoxicité) entraînant une surdité"
  },
  {
    "Drugs": [{ "name": "fremanezumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "frusemide (furosemide)" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "fulvestrant" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "furosemide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "fusidic acid" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "FVIII inhibitor bypassing fraction" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gabapentin" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gadobenate" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gadobutrol" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gadodiamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gadofosveset" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gadopentetate dimeglumine" }],
    "Category": "B2",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gadoteridol" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gadoversetamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gadoxetate" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "galactose with palmitic acid" }],
    "Category": "B2",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "galantamine" }],
    "Category": "B1",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "galcanezumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gallamine" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "galsulfase" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ganciclovir" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ganirelix" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gatifloxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "gefitinib" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gelatin - succinylated" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gemcitabine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gemeprost" }],
    "Category": "B3",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Agents acting on the uterus",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gemfibrozil" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gemtuzumab ozogamicin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gentamicin" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Aminoglycosides",
    "Observation": "Lésions de l’oreille fœtale (ototoxicité) entraînant une surdité"
  },
  {
    "Drugs": [{ "name": "gestoden" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Progestogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gestrinone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glatiramer" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glecaprevir" }, { "name": "pibrentasvir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glibenclamide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glibenclamide" }, { "name": "metformin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gliclazide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glimepiride" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glipizide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glucagon" }],
    "Category": "B3",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glyceryl trinitrate" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiangina agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glyceryl trinitrate" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glycopyrronium bromide" }],
    "Category": "B2",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antispasmodics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glycopyrronium bromide" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "glycopyrronium bromide" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "glycopyrronium bromide" },
      { "name": "formoterol fumarate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "golimumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gonadotrophin - human chorionic" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Ovulation inducers",
    "ClassificationLevel3": "Gonadotrophins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "gonadotrophin - human menopausal" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Ovulation inducers",
    "ClassificationLevel3": "Gonadotrophins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "goserelin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "goserelin" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "granisetron" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "griseofulvin" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "guaifenesin" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Expectorants and mucolytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "guanethidine" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "guanfacine hydrochloride" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "guselkumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "Haemophilus influenzae type b conjugate vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      {
        "name": "Haemophilus influenzae type b-meningococcal group C conjugate vaccine"
      }
    ],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "halcinonide" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Topical",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "haloperidol" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Butyrophenones",
    "Observation": "Effets néfastes observés chez les animaux. Lorsque l’halopéridol est administré au cours du premier trimestre, possibles malformations congénitales des membres. Lorsque l’halopéridol est administré au cours du troisième trimestre, augmentation du risque des pathologies suivantes : \n - Mouvements répétitifs involontaires (symptômes extrapyramidaux) \n -Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né en raison de l’interruption du passage du médicament dans le placenta"
  },
  {
    "Drugs": [{ "name": "halothane" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "heparin" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus. Thrombocytopénie (réduction du nombre de plaquettes qui participent à la coagulation) chez la femme enceinte, entraînant parfois un saignement excessif"
  },
  {
    "Drugs": [{ "name": "hepatitis A - hepatitis B vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hepatitis A - typhoid vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hepatitis A vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hepatitis B vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "homatropine" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "house dust mite allergen extract" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "human papillomavirus vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hydralazine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hydrochlorothiazide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "hydrocortisone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Systemic",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "hydromorphone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "hydroxycarbamide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hydroxychloroquine" }],
    "Category": "D",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Antirheumatoid agents",
    "ClassificationLevel3": "",
    "Observation": "Pas de risque accru aux doses généralement administrées"
  },
  {
    "Drugs": [{ "name": "hydroxychloroquine (antimalarial)" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": "Pas de risque accru aux doses généralement administrées"
  },
  {
    "Drugs": [{ "name": "hydroxyprogesterone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Progestogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "hydroxyurea (hydroxycarbamide)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hydroxyzine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hyoscine" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hyoscine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hyoscine hydrobromide" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hyoscine methobromide" }],
    "Category": "A",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hyoscine-N-butylbromide" }],
    "Category": "B2",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antispasmodics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hyoscine-N-butylbromide" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hyoscyamine" }],
    "Category": "B2",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "hyoscyamine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ibandronate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "Bisphosphonates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ibrutinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ibuprofen" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "ibutilide" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "icatibant" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "idarubicin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "idarucizumab" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "idelalisib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "idoxuridine (ophthalmic)" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "idoxuridine (topical)" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiviral",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "idursulfase" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ifosfamide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iloprost" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "imatinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "imiglucerase" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "imipenem with cilastatin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "imipramine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "imiquimod" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiviral",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "inactivated influenza vaccine (pandemic)" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "inactivated influenza vaccine (pre-pandemic)" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "inactivated influenza vaccine (seasonal)" },
      { "name": "split" },
      { "name": "trivalent or quadrivalent" }
    ],
    "Category": "A",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "inactivated influenza vaccine (seasonal)" },
      { "name": "surface antigen" },
      { "name": "trivalent or quadrivalent" }
    ],
    "Category": "B1 or B2 (depending on brand of vaccine)",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "inclisiran" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "incobotulinumtoxinA" }],
    "Category": "B3",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "indacaterol" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "indacaterol maleate" },
      { "name": "glycopyrronium bromide" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "indacaterol" }, { "name": "glycopyrronium" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "indapamide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "indigo carmine" }],
    "Category": "B2",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "indinavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "indometacin" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "infigratinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "infliximab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      {
        "name": "influenza virus A (H1N1)"
      },
      { "name": "influenza virus A (H3N2)" },
      { "name": "influenza virus B (Yamagata-lineage)" },
      {
        "name": "influenza virus B (Victoria lineage) quadrivalent vaccine (live-attenuated)"
      }
    ],
    "Category": "B1",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ingenol" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "inotuzumab ozogamicin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "insulin aspart" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "Insulins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "insulin aspart" }, { "name": "insulin degludec" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "Insulins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "insulin detemir" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "Insulins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "insulin glargine" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "Insulins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "insulin glulisine" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "Insulins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "insulin lispro" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "Insulins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "interferon alpha-2a" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "interferon alpha-2b" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "interferon beta-1a" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "interferon beta-1b" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "interferon gamma-1b" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iodixanol" }],
    "Category": "B1",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iodoform with bismuth subnitrate" }],
    "Category": "D",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iomeprol" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iopromide" }],
    "Category": "B2",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ioversol" }],
    "Category": "B1",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ipecacuanha" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Expectorants and mucolytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ipilimumab" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ipratropium bromide" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "irbesartan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin II receptor antagonists and renin inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "irinotecan" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "irinotecan (nanoliposomal as sucrosofate)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iron [as ferric derisomaltose] (parenteral)" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iron polymaltose (oral)" }],
    "Category": "A",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iron polymaltose (parenteral)" }],
    "Category": "A",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "iron sucrose (parenteral)" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isatuximab" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isavuconazole" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isoconazole" }],
    "Category": "B2",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Topical vaginal medication",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isoflurane" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isoniazid" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antituberculotics and antileprotics",
    "ClassificationLevel3": "",
    "Observation": "Possibilité d’effets néfastes sur le foie ou de lésions des nerfs périphériques (provoquant des sensations anormales et/ou une faiblesse)"
  },
  {
    "Drugs": [{ "name": "isoprenaline" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isoprenaline" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isosorbide dinitrate" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiangina agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isosorbide dinitrate" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isosorbide mononitrate" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiangina agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isotretinoin (systemic)" }],
    "Category": "X",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Systemic",
    "ClassificationLevel3": "",
    "Observation": "Malformations congénitales telles que malformations cardiaques, petites oreilles et hydrocéphalie. Déficit intellectuel. Risque de fausse couche"
  },
  {
    "Drugs": [{ "name": "isotretinoin (topical)" }],
    "Category": "D",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": "Malformations congénitales telles que malformations cardiaques, petites oreilles et hydrocéphalie. Déficit intellectuel. Risque de fausse couche"
  },
  {
    "Drugs": [{ "name": "isoxsuprine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "isradipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "itraconazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ivabradine" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiangina agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ivacaftor" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "ivacaftor" },
      { "name": "tezacaftor" },
      { "name": "elexacaftor" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ivermectin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Anthelmintics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ixazomib" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ixekizumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "Japanese encephalitis vaccine (inactivated)" }],
    "Category": "B1",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "Japanese encephalitis vaccine (live" },
      { "name": "attenuated)" }
    ],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "kanamycin" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Aminoglycosides",
    "Observation": "Lésions de l’oreille fœtale (ototoxicité) entraînant une surdité"
  },
  {
    "Drugs": [{ "name": "ketamine" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ketoconazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ketoprofen" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "ketorolac" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "ketotifen" }],
    "Category": "B1",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "labetalol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "lacosamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lamivudine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lamotrigine" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Pas d’augmentation substantielle du risque de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "lanadelumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lanreotide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lansoprazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lanthanum" }],
    "Category": "B3",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lapatinib" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "laronidase" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "larotrectinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "latanoprost" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "latanoprost" }, { "name": "timolol" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lauromacrogol" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ledipasvir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ledipasvir" }, { "name": "sofosbuvir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "ledipasvir" },
      { "name": "sofosbuvir with ribavirin" }
    ],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "leflunomide" }],
    "Category": "X",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lemborexant" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lemborexant" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lenalidomide" }],
    "Category": "X",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lenograstim" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lenvatinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lepirudin" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "lercanidipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "AntihypertensivesCalcium channel blockers",
    "ClassificationLevel3": "",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "lesinurad" }],
    "Category": "B1",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Agents used in gout and hyperuricaemia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "letermovir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "letrozole" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "leuprorelin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "levamisole" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "levetiracetam" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Anomalies osseuses mineures observées chez l’animal. Aucune augmentation significative du risque chez l’homme"
  },
  {
    "Drugs": [{ "name": "levobunolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "levobunolol (ophthalmic)" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "levobupivacaine" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "levocabastine" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "levocabastine (ophthalmic)" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "levocetirizine" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "levodopa" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "levonorgestrel" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Oral contraceptives",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "levonorgestrel" }, { "name": "ethinyloestradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Oral contraceptives",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "lidocaine" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lidocaine" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lifitegrast" }],
    "Category": "B1",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lignocaine (lidocaine)" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lignocaine (lidocaine)" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "linagliptin" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "linagliptin" }, { "name": "metformin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lincomycin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lindane" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiparasitics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "linezolid" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "liothyronine" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Thyroid hormones",
    "ClassificationLevel3": "",
    "Observation": "Glande thyroïde augmentée de volume et hyperactive chez le fœtus"
  },
  {
    "Drugs": [{ "name": "lipegfilgrastim" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "liraglutide (rys)" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lisdexamfetamine dimesilate" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "CNS stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lisinopril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "lithium salts" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": "Lorsque le lithium est administré au cours du premier trimestre, augmentation du risque de malformations congénitales (principalement du cœur). Lorsque le lithium est administré plus tard au cours de la grossesse, somnolence, baisse du tonus musculaire, perte de l’appétit, baisse d’activité de la thyroïde et diabète insipide néphrogénique chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "lixisenatide with insulin glargine" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lodoxamide trometamol" }],
    "Category": "B1",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lomustine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lonoctocog alfa" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "loperamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lopinavir with ritonavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "loracarbef" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Cephalosporins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "loratadine" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": "Chez les garçons, malformation congénitale possible de l’urètre, dans le cadre de laquelle l’ouverture de l’urètre est mal placée sur le pénis (hypospadias)"
  },
  {
    "Drugs": [{ "name": "lorazepam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "lorlatinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "losartan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin II receptor antagonists and renin inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "lumacaftor" }, { "name": "ivacaftor" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lumiracoxib" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "lurasidone hydrochloride" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": "Aucune preuve d’effets nocifs chez les animaux. Lorsque la lurasidone est administrée au cours du troisième trimestre, augmentation du risque des pathologies suivantes :\n - Mouvements répétitifs involontaires\n - Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né en raison de l’interruption du passage du médicament dans le placenta"
  },
  {
    "Drugs": [{ "name": "lurbinectedin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lutetium (177Lu) chloride" }],
    "Category": "X",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lutropin alfa" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "lypressin" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antidiuretics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "macitentan" }],
    "Category": "X",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Endothelin receptor antagonist",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "macrogol" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Laxatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "malathion" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiparasitics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mannitol" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "maraviroc" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mazindol" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Anorectic and weight reducing agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "measles-mumps-rubella vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": "Infections possibles placentaires et du fœtus"
  },
  {
    "Drugs": [{ "name": "measles-mumps-rubella-varicella vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": "Infections possibles placentaires et du fœtus"
  },
  {
    "Drugs": [{ "name": "mebendazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Anthelmintics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mebeverine" }],
    "Category": "B2",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antispasmodics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mecasermin" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hormonal agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "medroxyprogesterone (IM contraceptive dose)" }],
    "Category": "A",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicaleSi ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "medroxyprogesterone (oral & SC high dose)" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Progestogens (see also oral contraceptives)",
    "ClassificationLevel3": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "medroxyprogesterone (oral and IM high dose)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "mefenamic acid" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "mefloquine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mefruside" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "megestrol" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Progestogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "melatonin" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "meloxicam" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "melphalan" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "memantine" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "meningococcal group B vaccine" }],
    "Category": "B1",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "meningococcal group C conjugate vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "meningococcal serogroups A" },
      { "name": "C" },
      { "name": "W-135 and Y polysaccharide or conjugate vaccine" }
    ],
    "Category": "B1 orB2 depending on brand",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mepivacaine" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mepolizumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "meprobamate" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mercaptamine bitartrate" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mercaptopurine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": "Anomalies congénitales comme un développement insuffisant de la mandibule, une fente palatine, une anomalie de développement des os du crâne, des anomalies de la colonne vertébrale, de l’oreille et un pied bot. Croissance insuffisante du fœtus (retard de croissance)"
  },
  {
    "Drugs": [{ "name": "meropenem" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mesalazine" }],
    "Category": "C",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mesna" }],
    "Category": "B1",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Non-cytotoxic supportive therapy",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mesterolone" }],
    "Category": "X",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Androgens and anabolic steroids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mestranol" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "metaraminol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "metformin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methacycline" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Tetracyclines",
    "Observation": "Ralentissement de la croissance osseuse, jaunissement permanent des dents et augmentation du risque de caries chez l’enfant. Parfois, insuffisance hépatique chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "methadone" }],
    "Category": "C",
    "ClassificationLevel1": "Agents used in dependency states",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "methadone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "methdilazine" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methenamine" }],
    "Category": "A",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Urinary antiseptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methenolone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Androgens and anabolic steroids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methocarbamol" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methohexitone" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methotrexate" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": "Anomalies congénitales comme un développement insuffisant de la mandibule, une fente palatine, une anomalie de développement des os du crâne, des anomalies de la colonne vertébrale, de l’oreille et un pied bot. Croissance insuffisante du fœtus (retard de croissance)"
  },
  {
    "Drugs": [{ "name": "methoxsalen" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methoxsalen (ECP extracorporeal photopheresis)" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methoxy polyethylene glycol-epoetin beta" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methoxyflurane" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methsuximide" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methyclothiazide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "methyl aminolevulinate" }],
    "Category": "B2",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methyldopa" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methylene blue" }],
    "Category": "D",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methylnaltrexone" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methylphenidate" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "CNS stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methylphenobarbital" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Risque accru d’anomalies congénitales, notamment des malformations du tube neural (comme le spina bifida). Troubles hémorragiques chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "methylphenobarbitone (methylphenobarbital)" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Risque accru d’anomalies congénitales, notamment des malformations du tube neural (comme le spina bifida). Troubles hémorragiques chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "methylprednisolone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Systemic",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "methylprednisolone aceponate" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Topical",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "methyltestosterone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Androgens and anabolic steroids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "methysergide" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "metoclopramide" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "metolazone" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "metoprolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "metronidazole" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "metyrapone" }],
    "Category": "B2",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Pituitary-adrenal response test",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mexiletine" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mezlocillin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mianserin" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tetracyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "micafungin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "miconazole" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": "Aucune augmentation du risque de malformations congénitales lorsqu’il est appliqué sur la peau. Lorsqu’il est pris par voie orale, effets secondaires lors des études chez l’animal. Lorsqu’il est inséré dans le vagin, aucun risque accru de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "miconazole" }],
    "Category": "A",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Topical vaginal medication",
    "ClassificationLevel3": "",
    "Observation": "Aucune augmentation du risque de malformations congénitales lorsqu’il est appliqué sur la peau. Lorsqu’il est pris par voie orale, effets secondaires lors des études chez l’animal. Lorsqu’il est inséré dans le vagin, aucun risque accru de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "midazolam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "midodrine hydrochloride" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "midostaurin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "migalastat hydrochloride" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "miglitol" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "miglustat" }],
    "Category": "D",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "milnacipran" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "milrinone" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Cardiac inotropic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "minocycline" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Tetracyclines",
    "Observation": "Ralentissement de la croissance osseuse, jaunissement permanent des dents et augmentation du risque de caries chez l’enfant. Parfois, insuffisance hépatique chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "minoxidil" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mirabegron" }],
    "Category": "B3",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Bladder function disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mirtazapine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "misoprostol" }],
    "Category": "X",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mitomycin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mitozantrone" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antibiotic cytotoxic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mivacurium" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "moclobemide" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "modafinil" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "CNS stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mogamulizumab" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "molgramostim" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "molnupiravir" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mometasone" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Topical",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "montelukast" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "moroctocog alfa (factor VIII - rch)" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "morphine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal-anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "moxifloxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "moxonidine" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "multicomponent meningococcal group B vaccine (recombinant" },
      { "name": "adsorbed)" }
    ],
    "Category": "B1",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mupirocin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mustine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mycophenolate mofetil" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "mycophenolic acid" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nabiximols" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nabumetone" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "nadroparin" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "nafarelin" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nalidixic acid" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "naloxone" }],
    "Category": "B1",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "naltrexone" }],
    "Category": "B3",
    "ClassificationLevel1": "Agents used in dependency states",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nandrolone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Androgens and anabolic steroids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "naproxen" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "naratriptan" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "natalizumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nateglinide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nebivolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "nedocromil" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Preventative aerosols and inhalations",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nefazodone" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nelfinavir" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "neomycin" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Aminoglycosides",
    "Observation": "Lésions de l’oreille fœtale (ototoxicité) entraînant une surdité"
  },
  {
    "Drugs": [{ "name": "neostigmine" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Myasthenia Gravis",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nepafenac" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "neratinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "neratinib maleate" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "netilmicin" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Aminoglycosides",
    "Observation": "Lésions de l’oreille fœtale (ototoxicité) entraînant une surdité"
  },
  {
    "Drugs": [{ "name": "netupitant" }, { "name": "palonosetron" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nevirapine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nicardipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "nicorandil" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiangina agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nicotine" }],
    "Category": "D",
    "ClassificationLevel1": "Agents used in dependency states",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nicotinic acid" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nicotinic acid" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nicotinic acid" }],
    "Category": "B2",
    "ClassificationLevel1": "Vitamins",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nicotinyl alcohol" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nifedipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "nilotinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nimodipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "nintedanib esilate" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "niraparib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nirmatrelvir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nisoldipine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "nitisinone" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nitrazepam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "nitric oxide" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nitrofurantoin (short term therapy)" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": "Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD)"
  },
  {
    "Drugs": [{ "name": "nitrous oxide" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nivolumab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nizatidine" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nomegestrol with estradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "nonacog alfa (rch)" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nonacog gamma (rch)" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nonoxinol 9" }],
    "Category": "A",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Vaginal spermicides",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "norelgestromin with ethinylestradiol" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "norethisterone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Progestogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "norfloxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "nortriptyline" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nusinersen" }],
    "Category": "B1",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nystatin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "nystatin" }],
    "Category": "A",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Topical vaginal medication",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "obeticholic acid" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "obinutuzumab" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ocrelizumab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ocriplasmin" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "octocog alfa (factor VIII - rch)" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "octoxinol" }],
    "Category": "A",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Vaginal spermicides",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "octreotide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oestrone" }],
    "Category": "B1",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ofatumumab (rmc)" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ofloxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "olanzapine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": "Effets néfastes observés chez les animaux. Lorsque l’olanpazine est administrée au cours du troisième trimestre, augmentation du risque des pathologies suivantes : \n - Mouvements répétitifs involontaires \n - Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né en raison de l’interruption du passage du médicament dans le placenta"
  },
  {
    "Drugs": [{ "name": "olaparib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "olmesartan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin II receptor antagonists and renin inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "olodaterol (olodaterol hydrochloride)" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "olodaterol" }, { "name": "tiotropium bromide" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "olopatadine" }],
    "Category": "B1",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "olsalazine" }],
    "Category": "C",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "omalizumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "omega-3-acid ethyl esters 90" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "omeprazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "onasemnogene abeparvovec" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ondansetron" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": "Aucune preuve concluante de malformations congénitales chez l’animal. Lorsque l’ondansétron est administré au cours du premier trimestre, risque possible de cardiopathie congénitale"
  },
  {
    "Drugs": [{ "name": "opicapone" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "opium alkaloids and derivatives" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Antitussives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oral contraceptives" }, { "name": "combined" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Oral contraceptives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "orciprenaline" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "orciprenaline" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "orlistat" }],
    "Category": "B1",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Anorectic and weight reducing agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ornipressin" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "orphenadrine" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oseltamivir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "osimertinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxaliplatin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxandrolone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Androgens and anabolic steroids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxazepam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "oxcarbazepine" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxpentifylline (pentoxifylline)" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxprenolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "oxybuprocaine" }],
    "Category": "D",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxybutynin" }],
    "Category": "B1",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Bladder function disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxycodone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "oxycodone" }, { "name": "naloxone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal and anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "oxymetholone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Androgens and anabolic steroids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxyquinoline sulfate" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antifungals, antiseptics (see also antifungal agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "oxytetracycline" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Tetracyclines",
    "Observation": "Ralentissement de la croissance osseuse, jaunissement permanent des dents et augmentation du risque de caries chez l’enfant. Parfois, insuffisance hépatique chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "oxytocin" }],
    "Category": "A",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Agents acting on the uterus",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ozanimod" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "paclitaxel" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "palbociclib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "palifermin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Non-cytotoxic supportive therapy",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "paliperidone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "palonosetron" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pamidronate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "Bisphosphonates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pancuronium" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "panitumumab" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "panobinostat" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pantoprazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "papaveretum" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "papaverine" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "papaverine" }],
    "Category": "B3",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "paracetamol" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "paracetomol" }, { "name": "tramadol" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal and anti-inflammatory agents)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "paraldehyde" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "parecoxib" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "paricalcitol" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "paritaprevir" },
      { "name": "ritonavir" },
      { "name": "ombitasvir" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "paritaprevir" },
      { "name": "ritonavir" },
      { "name": "ombitasvir with ribavirin" }
    ],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "paritaprevir" },
      { "name": "ritonavir" },
      { "name": "ombitasvir" },
      { "name": "dasabuvir" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "paritaprevir" },
      { "name": "ritonavir" },
      { "name": "ombitasvir" },
      { "name": "dasabuvir" },
      { "name": "ribavirin" }
    ],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "paroxetine" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Selective serotonin reuptake inhibitors (SSRIs)",
    "Observation": "Lorsque la paroxétine est administrée au cours du premier trimestre, risque accru de malformations congénitales, notamment cardiaques. Lorsque le médicament est administré au cours du troisième trimestre, syndrome de sevrage et hypertension artérielle pulmonaire persistante du nouveau-né"
  },
  {
    "Drugs": [{ "name": "pasireotide diaspartate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pasireotide embonate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "patiromer (as sorbitex calcium)" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pazopanib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pegaspargase" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pegfilgrastim" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "peginterferon alfa-2a" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "peginterferon alfa-2b" }],
    "Category": "B3",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "peginterferon beta-1a (rch)" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pegvaliase" }],
    "Category": "D",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pegvisomant" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pembrolizumab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pemetrexed" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "penciclovir" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiviral",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "penicillamine" }],
    "Category": "D",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "penicillamine" }],
    "Category": "D",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Antirheumatoid agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pentamidine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pentastarch" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pentazocine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "pentobarbitone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "Barbiturates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pentosan polysulfate sodium" }],
    "Category": "B1",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Bladder function disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pentoxifylline" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "peramivir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "perampanel hemisesquihydrate" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "perflutren" }],
    "Category": "B3",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pergolide" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "perhexiline" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiangina agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "periciazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "perindopril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "permethrin" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiparasitics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "perphenazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pertuzumab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pethidine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "phenelzine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Monoamine oxidase inhibitors",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenindione" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "pheniramine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenobarbital" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Risque accru d’anomalies congénitales, notamment des malformations du tube neural (comme le spina bifida). Troubles hémorragiques chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "phenobarbitone (phenobarbital)" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Risque accru d’anomalies congénitales, notamment des malformations du tube neural (comme le spina bifida). Troubles hémorragiques chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "phenolphthalein" }],
    "Category": "B2",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Laxatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenoperidine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also - non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "phenoxybenzamine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenoxymethylpenicillin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phensuximide" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phentermine" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Anorectic and weight reducing agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phentolamine" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenylbutazone" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "phenylephrine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenylephrine" }],
    "Category": "B2",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Decongestants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenylpropanolamine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenylpropanolamine" }],
    "Category": "B2",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Decongestants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "phenytoin sodium" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Risque accru de malformations congénitales (telles que fente labiale ou malformations cardiaques). Troubles hémorragiques chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "pholcodine" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Antitussives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "physostigmine" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pilocarpine" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pimecrolimus" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pimozide" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pindolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "pioglitazone" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pipecuronium" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "piperacillin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "piperacillin with tazobactam" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "piperazine oestrone sulfate (estropipate)" }],
    "Category": "B1",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Oestrogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "piperonyl butoxide" }],
    "Category": "B3",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiparasitics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pirfenidone" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "piroxicam" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "pitavastatin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pizotifen" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "plerixafor" }],
    "Category": "D",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "plitidepsin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "pneumococcal vaccine" },
      { "name": "23-valent polysaccharide or 10- or 13-valent conjugate" }
    ],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "podophyllotoxin" }],
    "Category": "D",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "Antimitotic agent",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "polatuzumab vedotin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "poliomyelitis vaccine (injection)" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": "Risques potentiels, mais inconnus"
  },
  {
    "Drugs": [{ "name": "poliomyelitis vaccine (oral)" }],
    "Category": "A",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": "Risques potentiels, mais inconnus"
  },
  {
    "Drugs": [{ "name": "pomalidomide" }],
    "Category": "X",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ponatinib (as hydrochloride)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "posaconazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pralatrexate" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pramipexole" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "prasugrel" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "pravastatin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "praziquantel" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Anthelmintics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "prazosin" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "prednisolone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Systemic",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "prednisone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Systemic",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "pregabalin" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "prilocaine (with or without felypressin)" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "primaquine phosphate" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": "Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD)"
  },
  {
    "Drugs": [{ "name": "primidone" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "probenecid" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Agents used in gout and hyperuricaemia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "probucol" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "procainamide" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "procaine benzylpenicillin" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "procaine hydrochloride" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "procaine penicillin (procaine benzylpenicillin)" }],
    "Category": "A",
    "ClassificationLevel1": "Antimicrobials\\Antibiotics",
    "ClassificationLevel2": "Penicillins",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "procarbazine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "prochlorperazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "procyclidine" }],
    "Category": "A",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "progesterone" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Progestogens (see also oral contraceptives)",
    "ClassificationLevel3": "",
    "Observation": "Si ce médicament est pris très précocement dans la grossesse, masculinisation des organes génitaux d’un fœtus de sexe féminin qui, parfois, nécessitent une correction chirurgicale"
  },
  {
    "Drugs": [{ "name": "progestogen only contraceptives" }],
    "Category": "B3",
    "ClassificationLevel1": "Contraceptive Agents",
    "ClassificationLevel2": "Oral contraceptives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "proguanil" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "promazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "promethazine" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": "Aucune preuve concluante de malformations congénitales chez l’animal. Risque possible de saignements chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "promethazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": "Aucune preuve concluante de malformations congénitales chez l’animal. Risque possible de saignements chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "propantheline" }],
    "Category": "B2",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antispasmodics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "propantheline" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "propofol" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "propranolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "propylthiouracil" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antithyroid agents",
    "ClassificationLevel3": "",
    "Observation": "Glande thyroïde augmentée de volume et déficitaire chez le fœtus. Lésions hépatiques chez la mère"
  },
  {
    "Drugs": [{ "name": "protamine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "protein c (human)" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "protriptyline" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "proxymetacaine" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "prucalopride" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Laxatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pseudoephedrine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": "Rétrécissement des vaisseaux sanguins dans le placenta susceptible de réduire la quantité d’oxygène et de substances nutritives reçue par le fœtus et donc d’entraîner une croissance inappropriée avant la naissance. Risque possible de malformation de la paroi abdominale laissant les intestins saillir à l’extérieur du corps (appelée gastroschisis)"
  },
  {
    "Drugs": [{ "name": "pseudoephedrine" }],
    "Category": "B2",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Decongestants",
    "ClassificationLevel3": "",
    "Observation": "Rétrécissement des vaisseaux sanguins dans le placenta susceptible de réduire la quantité d’oxygène et de substances nutritives reçue par le fœtus et donc d’entraîner une croissance inappropriée avant la naissance. Risque possible de malformation de la paroi abdominale laissant les intestins saillir à l’extérieur du corps (appelée gastroschisis)"
  },
  {
    "Drugs": [{ "name": "pyrantel embonate" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Anthelmintics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pyrazinamide" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antituberculotics and antileprotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pyrethrins" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical antiparasitics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pyridostigmine" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Myasthenia Gravis",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "pyrimethamine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "Q fever vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "quetiapine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "quinagolide" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "quinapril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "quinethazone" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Thiazides, related diuretics and loop diuretics",
    "Observation": "Diminution du taux d’oxygène, de sodium et de potassium, et du nombre de plaquettes dans le sang du fœtus. Croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "quinidine" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiarrhythmics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "quinine" }],
    "Category": "D",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Muscle relaxants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "quinine (treatment)" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rabeprazole" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "radium (223Ra) dichloride" }],
    "Category": "X",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "raloxifene" }],
    "Category": "X",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "raltegravir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "raltitrexed" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ramipril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "ramucirumab (rmc)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ranibizumab" }],
    "Category": "D",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ranitidine" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rasagiline" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rasburicase" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Agents used in gout and hyperuricaemia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ravulizumab" }],
    "Category": "B2",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "reboxetine" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "regdanvimab" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "regorafenib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "remdesivir" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "remifentanil" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also-non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "repaglinide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "reteplase" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Fibrinolytic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "retigabine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ribavirin" }],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ribociclib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rifabutin" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antituberculotics and antileprotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rifampicin" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antituberculotics and antileprotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rifaximin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rilpivirine" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "riluzole" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rimiterol" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rimiterol" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "riociguat" }],
    "Category": "X",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ripretinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "risankizumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "risdiplam" }],
    "Category": "D",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "risedronate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "Bisphosphonates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "risperidone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": "Effets néfastes observés chez les animaux. Aucune preuve de risque accru de malformations congénitales, mais aucune étude bien conçue n’a été menée chez la femme enceinte. Lorsque la rispéridone est administrée au cours du troisième trimestre, augmentation du risque des pathologies suivantes :\n - Mouvements répétitifs involontaires\n - Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né en raison de l’interruption du passage du médicament dans le placenta"
  },
  {
    "Drugs": [{ "name": "ritonavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rituximab" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rivaroxaban" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "rivastigmine" }],
    "Category": "B2",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rizatriptan" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rocuronium" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rofecoxib" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "romidepsin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "romiplostim" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "romosozumab" }],
    "Category": "B3",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Osteogenic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ropinirole" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ropivacaine" }],
    "Category": "B1",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Local anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rosiglitazone" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rosiglitazone" }, { "name": "metformin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rosuvastatin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rosuvastatin" }, { "name": "ezetimibe" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rotavirus vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rotigotine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "roxithromycin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Macrolide antibiotics",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rufinamide" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "rurioctocog alfa pegol" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ruxolitinib phosphate" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sacituzumab govitecan" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "safinamide (as mesilate)" }],
    "Category": "B3",
    "ClassificationLevel1": "",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "salbutamol" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "salbutamol" }],
    "Category": "A",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Agents acting on the uterus",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "salbutamol" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "salcatonin (calcitonin salmon)" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "salmeterol" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "salmeterol" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Preventative aerosols and inhalations",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "samarium [153Sm]" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "saponins" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Expectorants and mucolytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sapropterin" }],
    "Category": "B1",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "saquinavir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "satralizumab" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "saxagliptin" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "saxagliptin" }, { "name": "metformin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sebelipase alfa" }],
    "Category": "B1",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "secukinumab (rch)" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "selegiline" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "selexipag" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "semaglutide" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "senna" }],
    "Category": "A",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Laxatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sertindole" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sertraline" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Selective serotonin reuptake inhibitors (SSRIs)",
    "Observation": "Lorsque la sertraline est administrée au cours du troisième trimestre, syndrome de sevrage et hypertension artérielle pulmonaire persistante du nouveau-né"
  },
  {
    "Drugs": [{ "name": "sevelamer" }],
    "Category": "B3",
    "ClassificationLevel1": "Detoxifying Agents, Antidotes",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sevoflurane" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sibutramine" }],
    "Category": "C",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Anorectic and weight reducing agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sildenafil citrate" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "silodosin" }],
    "Category": "B3",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Prostate hyperplasia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "siltuximab" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "simeprevir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "simeprevir with ribavirin and peginterferon alfa" }],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "simvastatin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Hypolipidaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "siponimod" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sirolimus" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sitagliptin" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sitagliptin" }, { "name": "metformin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sitaxentan" }],
    "Category": "X",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Endothelin receptor antagonist",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "smallpox (Vaccinia) vaccine" }],
    "Category": "D",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sodium aurothiomalate" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Antirheumatoid agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sodium cromoglycate" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Preventative aerosols and inhalations",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sodium fusidate (fusidic acid)" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sodium nitroprusside" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sodium phenylbutyrate" }],
    "Category": "B3",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sodium phosphate [32P]" }],
    "Category": "X",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sodium salicylate" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "sodium valproate (valproic acid)" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": "Risque accru d’anomalies congénitales, notamment de fente palatine, de malformations du tube neural (comme le myéloméningocèle), et de malformations du cœur, du visage, du crâne, de la colonne vertébrale et des membres"
  },
  {
    "Drugs": [{ "name": "sofosbuvir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sofosbuvir" }, { "name": "velpatasvir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "sofosbuvir" },
      { "name": "velpatasvir" },
      { "name": "voxilaprevir" }
    ],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "sofosbuvir" },
      { "name": "velpatasvir with ribavirin" }
    ],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sofosbuvir with peginterferon alfa and ribavirin" }],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sofosbuvir with ribavirin" }],
    "Category": "X",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "solifenacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Prostate hyperplasia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "somatropin" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sorafenib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sotalol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "sotrovimab" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "spectinomycin" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "spironolactone" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Potassium sparing diuretics",
    "Observation": "Avec la spironolactone, développement possible de caractéristiques féminines chez les fœtus de sexe masculin"
  },
  {
    "Drugs": [{ "name": "spironolactone" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antiandrogens",
    "ClassificationLevel3": "",
    "Observation": "Avec la spironolactone, développement possible de caractéristiques féminines chez les fœtus de sexe masculin"
  },
  {
    "Drugs": [{ "name": "stavudine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "stiripentol" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "streptokinase" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Fibrinolytic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "strontium ranelate" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sucralfate" }],
    "Category": "B1",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Hyperacidity, reflux, ulcers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sucroferric oxyhydroxide" }],
    "Category": "B3",
    "ClassificationLevel1": "Blood and Haemopoietic System",
    "ClassificationLevel2": "Haemopoietic system",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sugammadex" }],
    "Category": "B2",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Antagonists of neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sulesomab" }],
    "Category": "B2",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sulfacetamide" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sulfadiazine" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Sulfonamides",
    "Observation": "Lorsque les médicaments sont donnés tardivement dans la grossesse, ictère et, en l’absence de traitement, atteintes cérébrales (ictère nucléaire) chez le nouveau-né, Risque de problèmes beaucoup moins probable avec la sulfasalazine, Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD)"
  },
  {
    "Drugs": [{ "name": "sulfadoxine" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Sulfonamides",
    "Observation": "Lorsque les médicaments sont donnés tardivement dans la grossesse, ictère et, en l’absence de traitement, atteintes cérébrales (ictère nucléaire) chez le nouveau-né, Risque de problèmes beaucoup moins probable avec la sulfasalazine, Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD)"
  },
  {
    "Drugs": [{ "name": "sulfamethizole" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Sulfonamides",
    "Observation": "Lorsque les médicaments sont donnés tardivement dans la grossesse, ictère et, en l’absence de traitement, atteintes cérébrales (ictère nucléaire) chez le nouveau-né, Risque de problèmes beaucoup moins probable avec la sulfasalazine, Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD)"
  },
  {
    "Drugs": [{ "name": "sulfamethoxazole" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Sulfonamides",
    "Observation": "Lorsque les médicaments sont donnés tardivement dans la grossesse, ictère et, en l’absence de traitement, atteintes cérébrales (ictère nucléaire) chez le nouveau-né, Risque de problèmes beaucoup moins probable avec la sulfasalazine, Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD)"
  },
  {
    "Drugs": [{ "name": "sulfasalazine" }],
    "Category": "A",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": "Lorsque les médicaments sont donnés tardivement dans la grossesse, ictère et, en l’absence de traitement, atteintes cérébrales (ictère nucléaire) chez le nouveau-né, Risque de problèmes beaucoup moins probable avec la sulfasalazine, Rupture (hémolyse) des globules rouges chez les femmes ou fœtus porteurs d’un déficit en glucose-6-phosphate déshydrogénase (G6PD)"
  },
  {
    "Drugs": [{ "name": "sulfinpyrazone" }],
    "Category": "B2",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Agents used in gout and hyperuricaemia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sulindac" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "sulthiame" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sumatriptan" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "sunitinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "susoctocog alfa" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "suxamethonium" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tacrine" }],
    "Category": "C",
    "ClassificationLevel1": "Cholinergic and Anticholinergic Agents",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tacrolimus" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tadalafil" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tafamidis" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tafenoquine" }],
    "Category": "C",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antimalarials",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tafluprost" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "talimogene laherparepvec (rmv)" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tamoxifen" }],
    "Category": "B3",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tamsulosin" }],
    "Category": "B2",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Prostate hyperplasia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tapentadol" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also - non-steroidal anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "tasonermin" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tazarotene" }],
    "Category": "D",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "technetium [99mTc]" }],
    "Category": "C",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "technetium [99mTc] albumin aggregated" }],
    "Category": "C",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "technetium [99mTc] bicisate" }],
    "Category": "C",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "teduglutide" }],
    "Category": "B1",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tegafur" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tegaserod" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Prokinetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "teicoplanin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "telaprevir" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "telbivudine" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "telmisartan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin II receptor antagonists and renin inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "telotristat ethyl (as etiprate)" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Antidiarrhoeals",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "temazepam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "temozolomide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "temsirolimus" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tenecteplase" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Fibrinolytic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "teniposide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  { "Drugs": [{ "name": "" }], "Observation": "" },
  {
    "Drugs": [{ "name": "tenofovir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      {
        "name": "tenofovir disoproxil fumarate"
      },
      { "name": "emtricitabine" },
      { "name": "elvitegravir" },
      { "name": "cobicistat" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tenoxicam" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "terazosin" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "terazosin" }],
    "Category": "B2",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Bladder function disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "terbinafine" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "terbutaline" }],
    "Category": "A",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Adrenergic stimulants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "terbutaline" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "terfenadine" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "teriflunomide" }],
    "Category": "X",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "teriparatide" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "terlipressin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "testosterone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Androgens and anabolic steroids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tetrabenazine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tetracaine" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tetracosactide" }],
    "Category": "D",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Pituitary-adrenal response test",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tetracosactrin (tetracosactide)" }],
    "Category": "D",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Pituitary-adrenal response test",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tetracycline" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Tetracyclines",
    "Observation": "Ralentissement de la croissance osseuse, jaunissement permanent des dents et augmentation du risque de caries chez l’enfant. Parfois, insuffisance hépatique chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "tezacaftor" }, { "name": "ivacaftor" }],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thalidomide" }],
    "Category": "X",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "theophylline and derivatives" }],
    "Category": "A",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thiabendazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Anthelmintics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thiethylperazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thiopentone" }],
    "Category": "A",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "General anaesthetics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thiopropazate" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thioridazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugsPhenothiazines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thiotepa" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Alkylating agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thiothixene" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thrombin" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thyrotrophin" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Pituitary hormones",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thyrotropin alfa" }],
    "Category": "B2",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "thyroxine" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Thyroid hormones",
    "ClassificationLevel3": "",
    "Observation": "Glande thyroïde augmentée de volume et hyperactive chez le fœtus"
  },
  {
    "Drugs": [{ "name": "tiagabine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tiaprofenic acid" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "tibolone" }],
    "Category": "D",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hormonal agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ticagrelor" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ticarcillin" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Penicillins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ticlopidine" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "tigecycline" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Tetracyclines",
    "Observation": "Ralentissement de la croissance osseuse, jaunissement permanent des dents et augmentation du risque de caries chez l’enfant. Parfois, insuffisance hépatique chez la femme enceinte"
  },
  {
    "Drugs": [{ "name": "tildrakizumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tilmanocept" }],
    "Category": "C",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tiludronate disodium" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "timolol" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Beta-adrenergic blocking agents",
    "ClassificationLevel3": "",
    "Observation": "Lorsque certains bêtabloquants sont administrés durant la grossesse, ralentissement de la fréquence cardiaque, faible taux de sucre dans le sang et, parfois, croissance insuffisante du fœtus (retard de croissance) et naissance prématurée. Tension artérielle basse chez la mère"
  },
  {
    "Drugs": [{ "name": "timolol (ophthalmic)" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tinidazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tinzaparin" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "tioguanine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tiotropium" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Bronchospasm relaxants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tipranavir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tirilazad" }],
    "Category": "B2",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tirofiban hydrochloride" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antiangina agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tisagenlecleucel" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tobramycin" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "AntibioticsAminoglycosides",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tocilizumab (rch)" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tofacitinib (as citrate)" }],
    "Category": "D",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tolazamide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tolbutamide" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tolcapone" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tolterodine" }],
    "Category": "B3",
    "ClassificationLevel1": "Genitourinary System",
    "ClassificationLevel2": "Prostate hyperplasia",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tolvaptan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "topiramate" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "topotecan" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "toremifene" }],
    "Category": "B3",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trabectedin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tramadol" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Analgesics and Antipyretics (see also non-steroidal - anti-inflammatory agents)",
    "ClassificationLevel3": "Opioid analgesics",
    "Observation": "Agitation, irritabilité, tremblements, difficultés respiratoires et troubles alimentaires (symptômes de sevrage médicamenteux) chez le nouveau-né, pouvant survenir de 6 heures à 8 jours après la naissance. Si des doses élevées sont administrées dans l’heure précédant l’accouchement, possible somnolence et bradycardie chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "trametinib dimethyl sulfoxide" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trandolapril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin converting enzyme (ACE) inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "tranexamic acid" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Haemostatic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tranylcypromine" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Monoamine oxidase inhibitors",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trastuzumab" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trastuzumab emtansine (rch)" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Monoclonal antibodies",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "travoprost" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "travoprost" }, { "name": "timolol" }],
    "Category": "C",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "treprostinil" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tretinoin" }],
    "Category": "D",
    "ClassificationLevel1": "Drugs used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tretinoin (oral)" }],
    "Category": "X",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "triamcinolone (inhaled)" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Inhalation/intranasal",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "triamcinolone (systemic)" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Systemic",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "triamcinolone (topical)" }],
    "Category": "A",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Corticosteroids",
    "ClassificationLevel3": "Topical",
    "Observation": "Fente labiale possible si ces médicaments sont pris au cours du premier trimestre"
  },
  {
    "Drugs": [{ "name": "triamterene" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Diuretics",
    "ClassificationLevel3": "Potassium sparing diuretics",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "triazolam" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Benzodiazepines",
    "ClassificationLevel3": "",
    "Observation": "Quand le médicament est pris en fin de grossesse, respiration très lente ou syndrome de sevrage (entraînant irritabilité, tremblements et réflexes exagérés) chez le nouveau-né"
  },
  {
    "Drugs": [{ "name": "trientine" }],
    "Category": "D",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trifarotene" }],
    "Category": "D",
    "ClassificationLevel1": "Drugs Used in Dermatology",
    "ClassificationLevel2": "Topical",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trifluoperazine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "Phenothiazines",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "trifluridine" },
      { "name": "tipiracil hydrochloride" }
    ],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Antimetabolites",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trihexyphenidyl" }],
    "Category": "B1",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiparkinson agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trimeprazine (alimemazine)" }],
    "Category": "C",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trimethoprim" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": "Malformations du cerveau et de la moelle épinière (malformations du tube neural), telles que le spina-bifida"
  },
  {
    "Drugs": [{ "name": "trimipramine" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "Tricyclic antidepressants",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "triprolidine" }],
    "Category": "A",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Antihistamines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "triptorelin" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Hormonal antineoplastic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "troglitazone" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tropicamide" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "tropisetron" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antiemetics, antinauseants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "trovafloxacin" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "Quinolones",
    "Observation": "Possibilité de malformations articulaires et osseuses (observées seulement chez les animaux)"
  },
  {
    "Drugs": [{ "name": "tubocurarine" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "typhoid vaccine (killed)" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Killed vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "typhoid vaccine (live attenuated" },
      { "name": "oral)" }
    ],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "umeclidinium bromide" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "Inhalational agents",
    "ClassificationLevel3": "Preventative aerosols and inhalations",
    "Observation": ""
  },
  {
    "Drugs": [
      {
        "name": "umeclidinium bromide"
      },
      { "name": "fluticasone furoate" },
      { "name": "vilanterol trifenatate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System Inhalational agents",
    "ClassificationLevel2": "Preventative aerosols and inhalations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [
      { "name": "umeclidinium bromide" },
      { "name": "vilanterol trifenatate" }
    ],
    "Category": "B3",
    "ClassificationLevel1": "Respiratory System Inhalationalnagents",
    "ClassificationLevel2": "Preventative aerosols and inhalations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "unoprostone isopropyl" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "upadacitinib" }],
    "Category": "D",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Antirheumatoid agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "urea [13C]" }],
    "Category": "B2",
    "ClassificationLevel1": "Diagnostic Agents",
    "ClassificationLevel2": "Radiographic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "urofollitrophin" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Ovulation inducers",
    "ClassificationLevel3": "Gonadotrophins",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "urokinase" }],
    "Category": "B1",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Fibrinolytic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ursodeoxycholic acid" }],
    "Category": "B3",
    "ClassificationLevel1": "Alimentary System",
    "ClassificationLevel2": "Cholelitholytics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ustekinumab" }],
    "Category": "B1",
    "ClassificationLevel1": "Allergy and immune system",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "valaciclovir" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "valdecoxib" }],
    "Category": "C",
    "ClassificationLevel1": "Musculoskeletal System",
    "ClassificationLevel2": "Non-steroidal anti-inflammatory drugs (NSAIDS)",
    "ClassificationLevel3": "",
    "Observation": "Si de fortes doses sont administrées, fausses couches possibles au cours du premier trimestre, retard du début du travail, fermeture précoce du canal qui relie l’aorte et l’artère pulmonaire (canal artériel), jaunisse, entérocolite nécrosante (lésion de la paroi de l’intestin) et, parfois, atteinte cérébrale chez le fœtus (ictère nucléaire) et signes hémorragiques chez la femme pendant et après l’accouchement et/ou chez le nouveau-né. Si les médicaments sont administrés en fin de grossesse, diminution de la quantité de liquide qui entoure le fœtus. Lorsque de faibles doses d’aspirine sont administrées, aucun risque significatif de malformations congénitales"
  },
  {
    "Drugs": [{ "name": "valganciclovir" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "valsartan" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Angiotensin II receptor antagonists and renin inhibitors",
    "Observation": "Si les médicaments sont administrés à la phase tardive de la grossesse, insuffisance rénale chez le fœtus, diminution de la quantité de liquide autour du fœtus en phase de développement (liquide amniotique) et malformations du visage, des membres et des poumons"
  },
  {
    "Drugs": [{ "name": "valsartan" }, { "name": "hydrochlorothiazide" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "valsartan" }, { "name": "sacubitril" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vancomycin" }],
    "Category": "B2",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antibiotics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vandetanib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vardenafil" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Vasodilators",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "varenicline" }],
    "Category": "B3",
    "ClassificationLevel1": "Agents used in dependency states",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "varicella vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": "Infections possibles placentaires et du fœtus"
  },
  {
    "Drugs": [{ "name": "vasopressin" }],
    "Category": "B2",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Antidiuretics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vecuronium" }],
    "Category": "C",
    "ClassificationLevel1": "Drugs Used in Anaesthesia",
    "ClassificationLevel2": "Neuromuscular blocking agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vedolizumab (rch)" }],
    "Category": "B2",
    "ClassificationLevel1": "Allergy and Immune System",
    "ClassificationLevel2": "Immunomodifiers",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "velaglucerase alfa" }],
    "Category": "B2",
    "ClassificationLevel1": "Metabolism",
    "ClassificationLevel2": "Agents used for the treatment of metabolic disorders",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vemurafenib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "venetoclax" }],
    "Category": "C",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "venlafaxine" }],
    "Category": "B2",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": "Lorsque la venlafaxine est administrée au cours du troisième trimestre, syndrome de sevrage"
  },
  {
    "Drugs": [{ "name": "verapamil" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antihypertensives",
    "ClassificationLevel3": "Calcium channel blockers",
    "Observation": "Lorsque des inhibiteurs calciques sont administrés au cours du premier trimestre, possibles malformations congénitales des doigts et/ou des orteils. Lorsque des inhibiteurs calciques sont administrés plus tard au cours de la grossesse, croissance insuffisante du fœtus"
  },
  {
    "Drugs": [{ "name": "vericiguat" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "verteporfin" }],
    "Category": "B3",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vigabatrin" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vildagliptin" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vildagliptin" }, { "name": "metformin" }],
    "Category": "C",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Hypoglycaemic agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vinblastine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Vinca alkaloids",
    "ClassificationLevel3": "",
    "Observation": "Possibilité de malformations congénitales (observées uniquement chez l’animal)"
  },
  {
    "Drugs": [{ "name": "vincristine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Vinca alkaloids",
    "ClassificationLevel3": "",
    "Observation": "Possibilité de malformations congénitales (observées uniquement chez l’animal"
  },
  {
    "Drugs": [{ "name": "vindesine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Vinca alkaloids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vinflunine" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Vinca alkaloids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vinorelbine tartrate" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Vinca alkaloids",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vismodegib" }],
    "Category": "X",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vitamin A" }],
    "Category": "D",
    "ClassificationLevel1": "Vitamins",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "voretigene neparvovec" }],
    "Category": "B2",
    "ClassificationLevel1": "Ophthalmic Drugs",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "voriconazole" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antifungal agents (see also topical antifungals)",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vorinostat" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "vortioxetine" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antidepressants",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "warfarin" }],
    "Category": "D",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus. Malformations congénitales, déficit intellectuel, cataractes et autres problèmes oculaires chez le fœtus."
  },
  {
    "Drugs": [{ "name": "ximelagatran" }],
    "Category": "C",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Anticoagulants and thrombolytic agents",
    "ClassificationLevel3": "",
    "Observation": "Risque possible de saignements chez la femme enceinte ou le fœtus"
  },
  {
    "Drugs": [{ "name": "yellow fever vaccine (live attenuated)" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": "Risques potentiels, mais inconnus"
  },
  {
    "Drugs": [{ "name": "zafirlukast" }],
    "Category": "B1",
    "ClassificationLevel1": "Respiratory System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zalcitabine" }],
    "Category": "D",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zaleplon" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zanamivir" }],
    "Category": "B1",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zanubrutinib" }],
    "Category": "D",
    "ClassificationLevel1": "Antineoplastic Agents",
    "ClassificationLevel2": "Tyrosine kinase inhibitors",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zidovudine" }],
    "Category": "B3",
    "ClassificationLevel1": "Antimicrobials",
    "ClassificationLevel2": "Antiviral agents",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "ziprasidone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Antipsychotic drugs",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zoledronic acid" }],
    "Category": "B3",
    "ClassificationLevel1": "Endocrine System",
    "ClassificationLevel2": "Agents affecting calcium and bone metabolism",
    "ClassificationLevel3": "Bisphosphonates",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zolmitriptan" }],
    "Category": "B3",
    "ClassificationLevel1": "Cardiovascular System",
    "ClassificationLevel2": "Antimigraine preparations",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zolpidem tartrate" }],
    "Category": "B3",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zonisamide" }],
    "Category": "D",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Anticonvulsants/antiepileptics",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zopiclone" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "Hypnotics and sedatives",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zoster vaccine" }],
    "Category": "B2",
    "ClassificationLevel1": "Vaccines",
    "ClassificationLevel2": "Live attenuated virus vaccines",
    "ClassificationLevel3": "",
    "Observation": ""
  },
  {
    "Drugs": [{ "name": "zuclopenthixol" }],
    "Category": "C",
    "ClassificationLevel1": "Central Nervous System",
    "ClassificationLevel2": "",
    "ClassificationLevel3": "",
    "Observation": ""
  }
]
